Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation patients. Vitamin K antagonists (such as warfarin) have been effective conventional oral anticoagulants for several decades. However, due to their limitations in clinical use, several nonvitamin K antagonist oral anticoagulants (NOACs, including dabigatran, rivaroxaban, apixaban and edoxaban) have been developed. Nonetheless, no head to head trials have been performed to directly compare these NOACs in patient cohorts. In this review article, two direct factor Xa inhibitors, apixaban and edoxaban, are briefly described with focus on their pharmacokinetic and pharmacodynamic profiles, plus drug interactions. Moreover, both efficacy and safety will be discussed based on the available data from the large Phase III clinical trials and indirect comparison studies.
University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.|Cardiovascular Department, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
Qinmei
Q
Xiong
University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Yee C
YC
Lau
University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.|Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Gregory Y H
GY
Lip
D001281:Atrial Fibrillation / Q000150:complications*; D065427:Factor Xa Inhibitors / Q000494:pharmacology*; D006801:Humans; D011720:Pyrazoles / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology*; D020521:Stroke / Q000150:complications* / Q000517:prevention & control*; D013844:Thiazoles / Q000494:pharmacology*
D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; C522181:apixaban; C552171:edoxaban
apixaban; atrial fibrillation; edoxaban